Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 10/27 10:00:04 pm
115.7 USD   +1.00%
06:11a JOHNSON & JOHNS : Jury awards more than $70M to woman in baby powder..
10/27 JOHNSON & JOHNS : Pinnacle Advisory Group buys $1,202,448 stake in J..
10/27 JOHNSON & JOHNS : JNJ) Faces Competition From Mylan Concerta Knockof..
News SummaryMost relevantAll newsSector news 

Biomet To Settle With DOJ, SEC On Bribery Charges For $22.7Mln

share with twitter share with LinkedIn share with facebook
share via e-mail
03/26/2012 | 05:50pm CEST

Medical-device company Biomet Inc. has agreed to pay about $22.7 million to settle civil and criminal charges stemming from allegations the company's units and agents bribed public doctors in Argentina, Brazil and China for nearly a decade to win business, the Department of Justice and the Securities and Exchange Commission said Monday.

The agencies allege that Biomet and its four units paid bribes from 2000 to August 2008, and employees and managers at all levels of the parent company and the units were involved, along with distributors. Biomet's compliance and internal audit functions failed to stop the payments to doctors even after learning about the illegal practices, the agencies alleged.

A Biomet representative wasn't immediately available for comment.

Biomet agreed to pay a $17.3 million criminal penalty for allegedly violating the Foreign Corrupt Practices Act. In its Justice Department agreement, it is required to implement rigorous internal controls, cooperate fully with the Justice Department and retain a compliance monitor for 18 months. Additionally, the company will pay $5.4 million in disgorgement of profits and prejudgment interest, as part of its separate SEC settlement.

Biomet, a privately held company that sells products used by orthopedic surgeons, is the third medical device firm to enter into a settlement with government agencies as part of the SEC and Justice Department's ongoing global investigation into medical-device companies allegedly bribing publicly employed physicians. Previously, Johnson & Johnson (>> Johnson & Johnson) and Smith & Nephew PLC (SNN, SN.LN) agreed to pay criminal penalties and entered into deferred prosecution agreements related to similar investigations, the Justice Department said.

In January, Biomet said its fiscal second-quarter loss widened as a drop in spine and bone-healing sales as well as higher costs masked the company's revenue growth.

-By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108; ben.rubin@dowjones.com

Stocks mentioned in the article : Johnson & Johnson
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
06:11a JOHNSON & JOHNSON : Jury awards more than $70M to woman in baby powder lawsuit
10/27 Johnson & Johnson Reports 2016 Third-Quarter Results
10/27 Verb Surgical Inc. Honored by Goldman Sachs for Entrepreneurship - Scott Huen..
10/27 JOHNSON & JOHNSON : Jules Musing, Former Senior Executive at Johnson & Johnson, ..
10/27 JOHNSON & JOHNSON : Pinnacle Advisory Group buys $1,202,448 stake in Johnson & J..
10/27 JOHNSON & JOHNSON (NYSE : JNJ) Faces Competition From Mylan Concerta Knockoff
10/26 JOHNSON & JOHNSON : to Participate in the 25th Annual Credit Suisse Health Care ..
10/26 JOHNSON & JOHNSON : Research Reports on Drug Makers Equities -- Pfizer, Merck, A..
10/24 JOHNSON & JOHNSON : Hepatitis B Virus Market (HBV) Review with 2016-2025 Forecas..
10/24 JOHNSON & JOHNSON : Davenport Co buys $162,560,871 stake in Johnson & Johnson
More news
Sector news : Pharmaceuticals - NEC
10/27DJPFIZER : Files 8K - Changes Executive Management
10/27 ASTRAZENECA : pauses two cancer drug trials' enrolment due to bleeding
10/27DJBRISTOL MYERS SQUIBB : Makes Moves to Reassure Investors
10/27DJBRISTOL MYERS SQUIBB : Makes Moves to Reassure Investors
10/27DJApple Unveils Macs With Touch-Screen Keyboard
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/27 Should You Buy Pfizer Now?
10/26 INSIDERINSIGHTS.COM DAILY ROUND UP 1 : Cree, mcc, reed, erc
10/26 GLOBAL BLOOD THERAPEUTICS : Incredible Value At This Price
10/26 Create Your Own Johnson & Johnson Dividend
10/26 After Positive P2B Results, Tiny, De-Risked Genocea Is Severely Undervalued
Financials ($)
Sales 2016 72 080 M
EBIT 2016 21 940 M
Net income 2016 16 371 M
Finance 2016 19 430 M
Yield 2016 2,71%
P/E ratio 2016 19,58
P/E ratio 2017 17,26
EV / Sales 2016 4,12x
EV / Sales 2017 3,84x
Capitalization 316 541 M
More Financials
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 126 $
Spread / Average Target 9,2%
Consensus details
EPS Revisions
More Estimates Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON12.64%316 541
ROCHE HOLDING LTD.-18.05%200 403
PFIZER INC.0.62%197 012
NOVARTIS AG-17.97%188 860
MERCK & CO., INC.16.04%169 480
SANOFI-12.39%96 780
More Results